Chutian Metropolis Daily reporter Jie Mingyue Correspondent Chen Ling Photography Chutian Metropolis Daily reporter Huang Shifeng
Character business card
Liu Binlei, Hubei University of Technology special professor and doctoral supervisor, selected for the Hubei Province "Hundred Talents Plan". He has served as a researcher of the National Health and Family Planning Commission and has undertaken many national science and technology plan projects.
He studied in the UK in his early years and developed the world's first oncolytic virus , which was approved for marketing in the United States and the European Union. He has been committed to the research on tumor immunology and oncolytic viruses for more than 20 years, reaching the international leading level, but resolutely gave up British nationality and returned to China to start a business. Now, he has developed the world's earliest and most successful original innovative drug to transform herpes simplex virus. "This new drug is about to enter clinical trials, and after it is launched, it may bring good news to millions of patients with solid tumors such as skin cancer, liver cancer, , and breast cancer." Liu Binlei said.
developed the world's first oncolytic virus approved for marketing
Liu Binlei studied at Wuhan Medical College (now Tongji Medical College of Huazhong University of Science and Technology), and then obtained a master's degree from Chinese Center for Disease Control and Prevention Nutrition and Food Safety. In 1992, after working as a visiting scholar at the Department of Molecular Microbiology at the University of Southampton, England, he began to pursue a doctorate and postdoctoral degree at the school.
"You must be able to endure loneliness and tests when doing scientific research." Liu Binlei recalled that at that time, he spent more than 10 hours every day, and it was common for him to stay in the laboratory for several consecutive days. When the experiment encountered a bottleneck, he also checked the documents all night and tried repeatedly. Sometimes the direction was wrong, and the efforts of several months might be wasted.
In 2000, Liu Binlei joined the British BoiVex Company and served as chief scientist of molecular biology two years later. The "Oncolytic Herpes Simplex Virus Tumor Treatment Injection" he was responsible for the development of "Oncolytic Herpes Simplex Virus Tumor Treatment Injection" is the world's first oncolytic virus to be proven effective through phase III clinical trials. In early 2011, the R&D result was acquired by Amgen, one of the world's largest biopharmaceutical companies, for US$1 billion and named T-Vec. T-Vec was approved in the United States and the European Union in 2015 and 2016, becoming the world's first oncolytic virus to be approved for marketing.
Helps Chinese production tumor immunotherapy new drug has made a major breakthrough
Liu Binlei said that although he has been in the UK for nearly 20 years, he has been looking for opportunities to return to China. In 2010, he gave up his British nationality and returned to the Institute of Cancer Hospital of the Chinese Academy of Medical Sciences as a researcher. "I have always wanted to start a business and hope that my R&D results will help more cancer patients." After multiple investigations, at the end of that year, Liu Binlei founded Wuhan Binhui Biotechnology Co., Ltd. and settled in Optical Valley Bio-City . After returning to China, he led his team to develop the "Oncolytic Type II Herpes Simplex Virus OH2" with higher oncolytic activity and stronger anti-tumor immune function. It was included in the "Class I innovative drug" and also received financial support for the creation of major new drugs in the country. "Class I is the first research and development internationally and domestically. This is the first tumor immunotherapy drug in the world using type II oncolytic herpes simplex virus as a vector." Liu Binlei introduced that at present, the project is about to enter clinical trials. After it is launched, the indications can be expanded to lung cancer, gastric cancer , esophageal cancer and other cancers, delaying the cancer process of patients.
As a professor and expert in the tumor biological treatment team of Hubei University of Technology, Liu Binlei pays great attention to the inheritance of technology. He has taught undergraduate courses such as " Microbiology " and "Instrument Analysis" in the school, and now he has 9 graduate students. Graduate student Cai Linkang said that Professor Liu is very responsible to students and listens to students' experimental reports every week and provides timely guidance.
